

NMOSD UNVEILED

Optimizing Long-Term Outcomes in Neuromyelitis Optica Spectrum Disorder with Innovative Therapies

May 29, 2024 • 4:00 - 5:30 PM CT

Music City Center • Karl F. Dean Ballroom A2



NMOSD UNVEILED

Optimizing Long-Term Outcomes in Neuromyelitis Optica Spectrum Disorder with Innovative Therapies

Neuromyelitis optica spectrum disorder (NMOSD) is a relatively new term for a group of rare, demyelinating autoimmune diseases affecting the central nervous system (CNS), particularly the optic nerves and spinal cord. In the past, NMOSD was conflated with multiple sclerosis (MS) due to significant similarities in early-stage presentation. However, recent evidence has shown NMOSD to be a unique disorder with an antibody-mediated etiology distinct from MS. Without proper diagnosis and treatment, patients with NMOSD are likely to develop significant and progressive disability with each recurrent attack.

Due to the relatively recent recognition of NMOSD as a distinct diagnostic entity, health care practitioners (HCPs) may lack knowledge and familiarity in its optimal diagnosis and management. It is essential that HCPs understand the etiology and pathophysiology of NMOSD, how novel therapies work to prevent NMOSD attacks, and long-term management strategies that can be utilized in clinical practice.

In this CME Outfitters live symposium, expert faculty will discuss strategies to better identify the pathological hallmarks of NMOSD, evaluate diagnostic criteria, utilize established and emerging therapeutics, and implement ongoing care of patients with NMOSD.

This symposium is neither sponsored nor endorsed by the Consortium of Multiple Sclerosis Centers.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

- Identify the pathophysiology of NMOSD including the role of the complement mechanism in the disease state
- Evaluate diagnostic criteria including clinical presentation, AQP4-IgG status, and magnetic resonance imaging (MRI) findings to accurately diagnose NMOSD
- Utilize recently approved and emerging NMOSD therapeutic antibodies in preventing acute episodes, associated damage, and long-term disability
- Implement ongoing care and monitoring of patients with NMOSD to optimize long-term outcomes

Target Audience

Adult neuroimmunologists, neuroradiologists, neurologists, internists, and ancillary HCPs – physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists

Financial Support

Supported by an educational grant from Alexion Pharmaceuticals.

Faculty

Rosemarie Walch, DO (Moderator)

Neuroimmunologist
Memorial Healthcare
Owosso, MI

Marijean Buhse, PhD, NP-BC, MSCN, FAAN

Nurse Practitioner
NYU South Shore Neurologic Associates
Islip, NY

Flavia Nelson, MD

Thomas F. Whigham-Joseph Berger Chair in Neuroimmunology
Professor of Neurology
Chief, CNS Autoimmune Disorders Division
Director, Multiple Sclerosis Center of Excellence
University of Miami Leonard M. Miller School of Medicine
Miami, FL

Patient/Patient Advocate

Chelsey Tucker

Artist, Author, and Patient Advocate

NMOSD UNVEILED

Optimizing Long-Term Outcomes in Neuromyelitis Optica Spectrum Disorder with Innovative Therapies

Credit Information

JOINTLY ACCREDITED PROVIDER



In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE CREDIT



This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education Credits for learning and change.

PHYSICIANS (ACCME)

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES (ANCC)

This activity is designated for 1.5 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC's provider number is CEP15510.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

PHARMACISTS

Pharmacists (ACPE): This application-based activity is approved for 1.5 contact hours (0.15 CEUs) of continuing pharmacy credit (JA0007185-0000-24-034-L01-P).

PAS (AAPA)



CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC CREDIT



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS IMPROVEMENT ACTIVITY



Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

ROYAL COLLEGE MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

NMOSD UNVEILED

Optimizing Long-Term Outcomes in Neuromyelitis Optica Spectrum Disorder with Innovative Therapies

Faculty



Rosemarie Walch, DO (Moderator)

Rosemarie Walch, DO, earned her doctor of osteopathic medicine degree from Michigan State University College of Osteopathic Medicine. She completed a neurology residency at Ascension Macomb-Oakland Hospital and a multiple sclerosis/neuroimmunology fellowship at the University of Cincinnati/UC Health Waddell Center for Multiple Sclerosis. She is currently a neuroimmunologist at Memorial Healthcare in Owosso, Michigan. Dr. Walch has published in peer-reviewed journals and has had numerous abstracts accepted for oral and poster presentations at many congresses.



Marijean Buhse, PhD, NP-BC, MSCN, FAAN

Dr. Marijean Buhse, PhD, ANP, RN, MSCN, FAAN, is a Clinical Professor and Director of the Doctoral Program in Nursing at Stony Brook University School of Nursing, Stony Brook, NY. She is also a Nurse Practitioner at NYU South Shore Neurologic working with persons with Multiple Sclerosis for over 25 years.

Dr. Buhse is the past president of the Multiple Sclerosis Nurses International Certification Board and the treasurer for the International Organization of MS Nurses. Her research has focused on closing existing gaps in knowledge related to care of older adults with multiple sclerosis.

NMOSD UNVEILED

Optimizing Long-Term Outcomes in Neuromyelitis Optica Spectrum Disorder with Innovative Therapies

Faculty



Flavia Nelson, MD

Flavia Nelson, MD, is a board-certified neurologist specializing in multiple sclerosis (MS) and other neuro-immunologic disorders. After receiving her medical degree from the University of Chihuahua (UACH) in Mexico, she completed a residency in Internal Medicine at Texas Tech University Health Sciences Center, and a neurology residency and a clinical/research fellowship in MS with Jerry Wolinsky at The Texas Medical Center, UT Houston. 12 years later she became the Interim Director of the Multiple Sclerosis Research Group this same institution, where she also co-directed the MRI-Analysis Center.

In 2022 Dr. Nelson moved to Minnesota and served as a member of the Center for MRI Research where she worked with UHF 7 and 10.5 magnets. She is a Professor of Neurology and Director of CNS Autoimmune Disorders and the MS Center of Excellence at the University of Miami.

Dr. Nelson serves as both a member and leader in several organizations related to multiple sclerosis and neurology. She is a trailblazer in the imaging of cortical gray matter lesions and their role on cognitive impairment. Her interests also include stem cell transplant in MS.

NMOSD UNVEILED

Optimizing Long-Term Outcomes in Neuromyelitis Optica Spectrum Disorder with Innovative Therapies

Patient/Patient Advocate



Chelsey Tucker

Diagnosed with a rare autoimmune disease, Neuromyelitis Optica Spectrum Disorder or NMOSD, which leaves her color blind and visually impaired, Chelsey Tucker uses emotion to feel the painting while creating. She paints as an expression of how she sees the world.

NMOSD doesn't just affect Chelsey's vision. During periods of relapse, those with NMOSD often lose feeling in their hands. While this may seem like a deterrent and a provocation to stop painting all together, this is not an option for Chelsey. She needs to create. Her subjects and methods may change depending on her symptoms, but this certainly does not prevent her from maintaining the same level of creativity and professionalism for which she is known. When holding a brush is no longer an option, she will use a technique involving her fingers directly on the canvas.

Residing just outside of Nashville, TN with her husband and their 5 children, Chelsey prioritizes family above all things. She derives a great deal of inspiration from her children, and they support her every step of the way. Chelsey is also a believer in giving back to her beloved NMOSD community as she serves as a patient influencer and rare disease advocate. In addition to advocating for the rare disease community, Chelsey is also an enthusiastic lover of horticulture—particularly flowers. She has provided plants and seeds for countless gardens within her community and enjoys creating hundreds of fresh floral arrangements throughout the growing season.

Most recently, her story and art have been featured in publications like *Vice* and *Women's Health Magazine*.

NMOSD UNVEILED

Optimizing Long-Term Outcomes in Neuromyelitis Optica Spectrum Disorder with Innovative Therapies

Disclosure Declarations

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Walch reports the following financial relationships:

- Advisory Board: Alexion Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Genentech, Inc./Roche; Genzyme Corporation; and Sanofi
- Consultant: Alexion Pharmaceuticals, Inc.; Amgen Inc./Horizon Therapeutics; and TG Therapeutics, Inc.
- Grants: CMSC Foundation
- Research Support: Alexion Pharmaceuticals, Inc.; Amgen Inc.; Biogen; EMD Serono; Genentech, Inc./Roche; Novartis. Pharmaceuticals Corporation; Roche; Sanofi; and TG Therapeutics, Inc.
- Speakers Bureau: Alexion Pharmaceuticals, Inc.; Amgen Inc./Horizon Therapeutics, Inc.; and Biogen

Dr. Buhse reports no financial relationships to disclose.

Dr. Nelson reports the following financial relationships:

- Advisory Board: Genentech, Inc. and Horizon Therapeutics

Ms. Tucker reports no financial relationships to disclose.

The following individuals have no financial relationships to disclose:

- Rebecca Vargas-Jackson, MD (Peer Reviewer)
- Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
- Evan Luburger (Planning Committee)
- Kellie Busby, PharmD, BCPP (Planning Committee)
- Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
- Sandra Caballero, PharmD (Planning Committee)
- Sharon Tordoff (Planning Committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the U.S. Food and Drug Administration (FDA). The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

NMOSD UNVEILED

Optimizing Long-Term Outcomes in Neuromyelitis Optica Spectrum Disorder with Innovative Therapies

Instructions for Interactive Technology

Use one of the iPads provided at your table to answer polling questions, view onsite presentations, and submit questions to the faculty. Please see additional information below.

1. ASK FACULTY A QUESTION

Select the Ask Question tab below the slide viewer to submit a question. If your question is for a specific faculty member, please include their name. Your question will be shared with the faculty for the question-and-answer portion of the session.

2. VIEW AND TAKE NOTES ON PRESENTATION SLIDES

Select the Take Notes tab to take notes during the meeting. All of the notes you take during the meeting will be emailed to the address provided within 5 business days.

Obtaining Credit

To receive CME/CE credit for this activity, scan the QR code to create an account.



Downloadable Resources

Downloadable resources will be available at:
www.cmeoutfitters.com/NMOSDresources

Engage with Us

Follow us @CMEOutfitters for announcements about upcoming CME opportunities, healthcare news, and more!

